Discounted Cash Flow
Rhythm Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $0 | $-29.1m | $-24.3m | — | — |
| 2017 | $0 | $-37.6m (-29.3%) | $-29.6m (-21.9%) | — | — |
| 2018 | $0 | $-74.1m (-97.1%) | $-62.8m (-112.1%) | — | — |
| 2019 | $0 | $-140.7m (-90.0%) | $-126.1m (-100.9%) | — | $-3.86 |
| 2020 | $0 | $-134.0m (4.8%) | $-122.2m (3.1%) | — | $-3.04 (21.2%) |
| 2021 | $3.2m | $-69.6m (48.0%) | $-146.4m (-19.8%) | -2207.1% | $-1.40 (53.9%) |
| 2022 | $23.6m (649.5%) | $-181.1m (-160.2%) | $-173.7m (-18.6%) | -766.2% (65.3%) | $-3.47 (-147.9%) |
| 2023 | $77.4m (227.6%) | $-184.7m (-2.0%) | $-136.2m (21.6%) | -238.5% (68.9%) | $-3.20 (7.8%) |
| 2024 | $130.1m (68.1%) | $-260.6m (-41.1%) | $-113.9m (16.4%) | -200.3% (16.0%) | $-4.34 (-35.6%) |
| 2025 | $189.8m (45.8%) | $-196.5m (24.6%) | $-116.6m (-2.4%) | -103.6% (48.3%) | $-3.11 (28.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.